

Effects of Psilocybin-Assisted Therapy on Major Depres

JAMA Psychiatry

78, 481

DOI: [10.1001/jamapsychiatry.2020.3285](https://doi.org/10.1001/jamapsychiatry.2020.3285)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. ACS Omega, 2020, 5, 32067-32075.	1.6	15
2	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews, 2021, 73, 202-277.	7.1	110
3	The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology and Translational Science, 2021, 4, 568-572.	2.5	223
4	People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy, 2021, 28, 215-226.	0.8	45
5	Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment. Chronic Stress, 2021, 5, 247054702110298.	1.7	19
6	Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Scientific Reports, 2021, 11, 1941.	1.6	76
7	Classics in Chemical Neuroscience: Amitriptyline. ACS Chemical Neuroscience, 2021, 12, 354-362.	1.7	20
9	A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT _{2A} Receptor Density in the Pig Brain. International Journal of Molecular Sciences, 2021, 22, 835.	1.8	96
10	Deep Network Pharmacology: Targeting Glutamate Systems as Integrative Treatments for Jump-Starting Neural Networks and Recovery Trajectories. Journal of Psychiatry and Brain Science, 2021, 6, .	0.3	0
11	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 2021, 35, 353-361.	2.0	49
12	Update on GPCR-based targets for the development of novel antidepressants. Molecular Psychiatry, 2021, , .	4.1	21
17	Dose-response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology, 2021, 35, 384-397.	2.0	38
18	Examining changes in personality following shamanic ceremonial use of ayahuasca. Scientific Reports, 2021, 11, 6653.	1.6	44
19	Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology, 2021, 35, 447-452.	2.0	41
20	The Promise of Psychedelic Science. ACS Pharmacology and Translational Science, 2021, 4, 413-415.	2.5	8
21	Hallucinogenic/psychedelic 5HT _{2A} receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Journal of Psychopharmacology, 2021, 35, 453-458.	2.0	30
22	The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Management and Healthcare Policy, 2021, Volume 14, 901-910.	1.2	31
23	Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacology and Translational Science, 2021, 4, 424-435.	2.5	109

#	ARTICLE	IF	CITATIONS
24	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology and Translational Science, 2021, 4, 543-552.	2.5	58
25	On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. ACS Pharmacology and Translational Science, 2021, 4, 436-451.	2.5	22
26	Identification of the Antidepressant Function of the Edible Mushroom <i>Pleurotus eryngii</i> . Journal of Fungi (Basel, Switzerland), 2021, 7, 190.	1.5	7
27	Crosstalk between Existential Phenomenological Psychotherapy and Neurological Sciences in Mood and Anxiety Disorders. Biomedicines, 2021, 9, 340.	1.4	32
28	Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 541-556.	1.8	21
29	Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT _{2R} activation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	173
30	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. Journal of Psychopharmacology, 2022, 36, 6-11.	2.0	28
31	Psilocybin: From Serendipity to Credibility?. Frontiers in Psychiatry, 2021, 12, 659044.	1.3	20
32	Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 2021, 384, 1402-1411.	13.9	643
33	Synthesis and Functional Characterization of 2-(2,5-Dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine (25H-NBF) Positional Isomers. ACS Chemical Neuroscience, 2021, 12, 1667-1673.	1.7	6
34	Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 569.	6.0	1
36	The Therapeutic Potential of Psilocybin. Molecules, 2021, 26, 2948.	1.7	78
37	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. International Journal of Neuropsychopharmacology, 2021, 24, 615-623.	1.0	20
38	The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology, 2022, 36, 309-320.	2.0	34
39	An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Molecular Psychiatry, 2021, 26, 6237-6252.	4.1	39
40	How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World Journal of Psychiatry, 2021, 11, 201-214.	1.3	21
42	Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. Journal of Psychopharmacology, 2022, 36, 74-84.	2.0	29
43	Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Irish Journal of Medical Science, 2022, 191, 1385-1397.	0.8	18

#	ARTICLE	IF	CITATIONS
44	Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use. <i>Addiction Research and Theory</i> , 2022, 30, 96-103.	1.2	11
45	Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. <i>Journal of Psychoactive Drugs</i> , 2022, 54, 81-92.	1.0	5
46	A dynamic and multilocus metabolic regulation strategy using quorum-sensing-controlled bacterial small RNA. <i>Cell Reports</i> , 2021, 36, 109413.	2.9	8
47	Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. <i>American Journal of Psychotherapy</i> , 2021, 74, 140-149.	0.4	46
48	Associations between lifetime classic psychedelic use and cardiometabolic diseases. <i>Scientific Reports</i> , 2021, 11, 14427.	1.6	24
50	Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. <i>Frontiers in Psychiatry</i> , 2021, 12, 661233.	1.3	41
51	Transtorno depressivo maior: diferentes possibilidades para pacientes resistentes ao tratamento. <i>Psi Unisc</i> , 2021, 5, 125-141.	0.0	0
52	Psychedelics for Brain Injury: A Mini-Review. <i>Frontiers in Neurology</i> , 2021, 12, 685085.	1.1	9
53	Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 793.	1.7	13
55	Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. <i>Pharmacopsychiatry</i> , 2021, 54, 240-245.	1.7	29
56	Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. <i>Neuron</i> , 2021, 109, 2535-2544.e4.	3.8	214
57	Sub-acute and long-term effects of ayahuasca on mental health and well-being in healthy ceremony attendants: A replication study. <i>Journal of Psychedelic Studies</i> , 2021, 5, 103-113.	0.5	9
58	Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1651-1660.	0.9	8
59	Treatment-Resistant Depression: Approaches to Treatment. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2021, 59, 7-11.	0.3	41
60	Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2022, 36, 20-30.	2.0	19
61	Global bioethical challenges of medicalising psychedelics. <i>Journal of Psychedelic Studies</i> , 2021, 5, 57-64.	0.5	3
62	Emerging approaches to the treatment of depression in patients with cardiovascular disease. <i>British Journal of Cardiac Nursing</i> , 2021, 16, 1-4.	0.0	0
63	Fungi and Algae as Sources of Medicinal and Other Biologically Active Compounds: A Review. <i>Nutrients</i> , 2021, 13, 3178.	1.7	25

#	ARTICLE	IF	CITATIONS
64	Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine. Culture, Medicine and Psychiatry, 2022, 46, 890-903.	0.7	11
65	A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.. F1000Research, 0, 10, 961.	0.8	6
67	A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing. Journal of Humanistic Psychology, 0, , 002216782110452.	1.4	22
68	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. Pharmaceuticals, 2021, 14, 985.	1.7	8
69	Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice. Epilepsy Research, 2021, 175, 106677.	0.8	7
70	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 2021, 50, 121-132.	0.3	57
71	Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?. , 2021, 7, 120-122.	0.1	0
72	Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. Frontiers in Psychiatry, 2021, 12, 716593.	1.3	5
73	Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs, 2022, 54, 309-318.	1.0	26
74	Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. Chronic Stress, 2021, 5, 247054702110356.	1.7	19
75	How ecstasy and psilocybin are shaking up psychiatry. Nature, 2021, 589, 506-509.	13.7	34
77	Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain, 2022, 145, 441-456.	3.7	82
78	Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Reports, 2021, 37, 109836.	2.9	82
79	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study" Frontiers in Psychiatry, 2021, 12, 735523.	1.3	33
80	Psychedelics and Other Psychoplastogens for Treating Mental Illness. Frontiers in Psychiatry, 2021, 12, 727117.	1.3	70
81	Prefrontal transcranial magnetic stimulation for depression in US military veterans " A naturalistic cohort study in the veterans health administration. Journal of Affective Disorders, 2022, 297, 671-678.	2.0	20
82	Psychedelic therapy: a roadmap for wider acceptance and utilization. Nature Medicine, 2021, 27, 1669-1671.	15.2	25
83	Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics. Current Treatment Options in Psychiatry, 2021, 8, 229-257.	0.7	1

#	ARTICLE	IF	CITATIONS
85	Toward a typology of hallucinogen users in the United States. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109139.	1.6	5
86	Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. <i>International Journal of Drug Policy</i> , 2022, 100, 103518.	1.6	10
87	Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction. <i>Sexual and Relationship Therapy</i> , 2022, 37, 314-323.	0.7	1
88	Molecular targets of psychedelic-induced plasticity. <i>Journal of Neurochemistry</i> , 2022, 162, 80-88.	2.1	15
89	Lysergic acid diethylamide induces increased signalling entropy in rats' prefrontal cortex. <i>Journal of Neurochemistry</i> , 2022, 162, 9-23.	2.1	6
90	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 886-895.	2.3	70
91	Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 574.	2.4	115
92	Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting. <i>Frontiers in Psychiatry</i> , 2021, 12, 720066.	1.3	9
93	Evolutionary Morphogenesis of Sexual Fruiting Bodies in Basidiomycota: Toward a New Evo-Devo Synthesis. <i>Microbiology and Molecular Biology Reviews</i> , 2022, 86, e0001921.	2.9	13
94	Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. <i>Pharmaceuticals</i> , 2021, 14, 1213.	1.7	15
95	Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness. <i>Journal of Psychiatric Practice</i> , 2021, 27, 448-452.	0.3	0
96	The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy. <i>Frontiers in Psychiatry</i> , 2021, 12, .	1.3	9
97	Neuropsychiatric Symptoms Exacerbate the Cognitive Impairments in Patients With Late-Life Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 757003.	1.3	4
98	Psychedelic-inspired approaches for treating neurodegenerative disorders. <i>Journal of Neurochemistry</i> , 2022, 162, 109-127.	2.1	17
99	Hallucinogen-Related Disorders. <i>Psychiatry Update</i> , 2022, , 41-56.	0.1	0
100	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. <i>Current Addiction Reports</i> , 2022, 9, 48-58.	1.6	7
101	Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. <i>Frontiers in Psychology</i> , 2021, 12, 749788.	1.1	13
102	Psychedelic medicines for mood disorders: current evidence and clinical considerations. <i>Current Opinion in Psychiatry</i> , 2022, 35, 22-29.	3.1	14

#	ARTICLE	IF	CITATIONS
103	A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration. <i>Journal of Psychedelic Studies</i> , 2021, , .	0.5	1
104	Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e056091.	0.8	7
105	Mechanisms of ketamine and its metabolites as antidepressants. <i>Biochemical Pharmacology</i> , 2022, 197, 114892.	2.0	66
106	The Potential of Psychedelics for End of Life and Palliative Care. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 169-184.	0.8	8
107	Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 1.	0.8	2
108	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
109	Dosing Psychedelics and MDMA. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 3-21.	0.8	12
110	Ayahuasca for the Treatment of Depression. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 113-124.	0.8	6
111	Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. <i>Pharmacopsychiatry</i> , 2022, 55, 193-202.	1.7	12
112	Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 11-18.	1.0	10
114	Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. <i>Psychopharmacology</i> , 2022, 239, 1907-1932.	1.5	36
115	Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. <i>Journal of Psychopharmacology</i> , 2022, 36, 57-65.	2.0	22
116	Psychedelics. <i>Current Biology</i> , 2022, 32, R63-R67.	1.8	26
117	Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 73-84.	1.0	7
118	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
119	Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. <i>Frontiers in Pharmacology</i> , 2021, 12, 749068.	1.6	16
120	Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. <i>Journal of Psychopharmacology</i> , 2022, 36, 31-45.	2.0	46
121	Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. <i>Biochemistry</i> , 2022, 61, 127-136.	1.2	41

#	ARTICLE	IF	CITATIONS
122	Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 19-29.	1.0	8
123	Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. <i>Journal of Psychoactive Drugs</i> , 2022, 54, 462-470.	1.0	1
124	Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. <i>Psychopharmacology</i> , 2022, 239, 1933-1943.	1.5	22
125	Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. <i>Frontiers in Neuroergonomics</i> , 2022, 2, .	0.6	4
126	Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. <i>Journal of Psychopharmacology</i> , 2022, 36, 66-73.	2.0	16
127	Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. <i>Addiction Biology</i> , 2022, 27, e13143.	1.4	28
128	Making Therapy Widely Available: Clinical Research Triumph or Existential Catastrophe?. <i>American Journal of Psychiatry</i> , 2022, 179, 79-82.	4.0	3
129	The Neglected Role of Psychotherapy for Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2022, 179, 90-93.	4.0	20
131	Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. <i>Journal of Xenobiotics</i> , 2022, 12, 41-52.	2.9	10
132	Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. <i>Fungal Biology</i> , 2022, 126, 308-319.	1.1	32
133	Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. <i>Cureus</i> , 2022, 14, e21944.	0.2	3
134	The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	2.1	31
135	Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 800072.	1.3	35
136	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. , 2022, 1, 100104.		12
137	Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452210852.	0.6	16
138	Human behavioral pharmacology of psychedelics. <i>Advances in Pharmacology</i> , 2022, 93, 105-132.	1.2	6
139	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. <i>Journal of Psychopharmacology</i> , 2022, 36, 151-158.	2.0	162
140	The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 40-50.	1.0	29

#	ARTICLE	IF	CITATIONS
141	Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 938.	1.0	17
142	Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice. <i>Translational Psychiatry</i> , 2022, 12, 77.	2.4	11
143	Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. <i>Neuropsychopharmacology</i> , 2022, 47, 1180-1187.	2.8	72
144	Microdosing as a Response to the Meaning Crisis: A Qualitative Analysis. <i>Journal of Humanistic Psychology</i> , 0, , 002216782210750.	1.4	6
145	Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. <i>Psychopharmacology</i> , 2022, 239, 1767-1782.	1.5	8
146	Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2022, 36, 337-347.	2.0	5
147	The promises and perils of psychedelic pharmacology for psychiatry. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 463-473.	21.5	82
148	Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. <i>Psychopharmacology</i> , 2022, 239, 1945-1976.	1.5	25
150	Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. <i>Science Advances</i> , 2022, 8, eabl6989.	4.7	34
151	Effects of an immersive psychosocial training program on depression and well-being: A randomized clinical trial. <i>Journal of Psychiatric Research</i> , 2022, 150, 292-299.	1.5	1
152	The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugsâ€™ effects on psychological flexibility. <i>Journal of Psychopharmacology</i> , 2022, 36, 387-408.	2.0	19
153	Can psychedelic-assisted psychotherapy play a role in enhancing motivation to change in addiction treatment settings?. <i>Journal of Psychedelic Studies</i> , 2022, , .	0.5	1
154	How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. <i>Psychopharmacology</i> , 2022, 239, 1853-1879.	1.5	5
155	Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. <i>Frontiers in Psychiatry</i> , 2022, 13, 831092.	1.3	20
156	Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 Âµg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2022, 36, 321-336.	2.0	11
157	Psilocybin-Assisted Compassion Focused Therapy for Depression. <i>Frontiers in Psychology</i> , 2022, 13, 812930.	1.1	19
158	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. <i>Frontiers in Pharmacology</i> , 2021, 12, 788155.	1.6	77
159	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. <i>Frontiers in Pharmacology</i> , 2022, 13, 841648.	1.6	29

#	ARTICLE	IF	CITATIONS
160	A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Australian and New Zealand Journal of Psychiatry, 2023, 57, 362-378.	1.3	12
161	Charismatic, Synchronous and Psychedelic Religious Experiences: A Personal Account. Religions, 2022, 13, 331.	0.3	0
162	Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology, 2022, 239, 1989-2010.	1.5	70
163	Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?. Expert Opinion on Drug Safety, 2022, , 1-4.	1.0	2
164	Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users. Journal of Psychoactive Drugs, 2023, 55, 170-179.	1.0	21
166	Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. , 2022, 3, 100044.		1
167	Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliative Care, 2021, 20, 191.	0.8	10
168	DÃ©pressionÂ: le pouvoir des champignons hallucinogÃªnes. , 2021, NÂ° 139, 24-31.		0
169	An upside-down binding mode to treat psychosis. Nature Neuroscience, 2022, 25, 4-6.	7.1	0
170	Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychotherapies. Journal of Neural Transmission, 2022, 129, 805-828.	1.4	3
171	A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.. F1000Research, 0, 10, 961.	0.8	0
172	Insular Stimulation Produces Mental Clarity and Bliss. Annals of Neurology, 2022, 91, 289-292.	2.8	5
173	Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channelâ€‘Mediated Cardiotoxicity. International Journal of Neuropsychopharmacology, 2022, 25, 280-282.	1.0	2
174	Progress Research on Poisoning Mechanism and Detection Methods of Poisonous Mushroom. Biophysics, 2022, 10, 15-21.	0.2	0
175	<i>JAMA Psychiatry</i>â€‘The Year in Review, 2021. JAMA Psychiatry, 2022, , .	6.0	0
176	Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Expert Opinion on Drug Safety, 2022, 21, 733-743.	1.0	8
177	Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, 2022, 21, 761-776.	1.0	13
178	Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey. Substance Use and Misuse, 2022, 57, 1072-1081.	0.7	7

#	ARTICLE	IF	CITATIONS
179	Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change?. Military Medicine, 2022, , .	0.4	1
180	Classical hallucinogens as antidepressant drugs: A cautionary approach. Current Neuropharmacology, 2022, 20, .	1.4	0
181	Will psilocybin lose its magic in the clinical setting?. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210908.	1.2	7
182	Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. Journal of Psychopharmacology, 2022, 36, 987-1000.	2.0	11
184	Psychedelic Mystical Experience: A New Agenda for Theology. Religions, 2022, 13, 385.	0.3	3
185	The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. Journal of Midwifery and Women's Health, 2022, 67, 373-383.	0.7	2
186	Magic mushroom extracts in lipid membranes. Biochimica Et Biophysica Acta - Biomembranes, 2022, 1864, 183957.	1.4	5
187	The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. Systematic Reviews, 2022, 11, 85.	2.5	2
188	Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. Neurolmage, 2022, 256, 119220.	2.1	39
189	Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. , 2022, 239, 108195.		20
190	The efficacy of psilocybin in the treatment of depression and anxiety: A meta-analysis. Current Psychiatry Research and Reviews, 2022, 18, .	0.1	0
191	If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. Journal of Pain, 2022, 23, 1666-1679.	0.7	8
192	Postpartum depression: A role for psychedelics?. Journal of Psychopharmacology, 2022, 36, 920-931.	2.0	2
193	Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus, 2022, , .	0.2	1
195	Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. Frontiers in Psychology, 2022, 13, .	1.1	41
196	Validity and reliability of the Dari version of the CES-D scale among the general population of Herat, Afghanistan: A methodological study. , 2022, 2, 10-19.		7
197	New Paradigms of Old Psychedelics in Schizophrenia. Pharmaceuticals, 2022, 15, 640.	1.7	22
198	Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers in Psychology, 2022, 13, .	1.1	24

#	ARTICLE	IF	CITATIONS
199	Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1854-1862.	2.8	64
200	The altered state of consciousness induced by Δ^9 -THC. <i>Consciousness and Cognition</i> , 2022, 102, 103357.	0.8	3
201	Integrating Social Justice into the Chemistry Curriculum: Setting the Ethical Foundation for Future Scientists. <i>ACS Symposium Series</i> , 0, , 41-61.	0.5	0
202	Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 213-227.	0.8	10
203	Should Adolescents be Included in Emerging Psychedelic Research?. <i>Canadian Journal of Bioethics</i> , 2022, 5, 36.	0.0	2
204	Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
206	Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E218-E221.	1.4	3
207	Novel ethical and policy issues in psychiatric uses of psychedelic substances. <i>Neuropharmacology</i> , 2022, 216, 109165.	2.0	21
208	Applying Lessons From Cannabis to the Psychedelic Highway. <i>JAMA Health Forum</i> , 2022, 3, e221618.	1.0	11
209	Psychedelic therapy for body dysmorphic disorder. <i>Journal of Psychedelic Studies</i> , 2022, 6, 23-30.	0.5	1
210	Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions. <i>Journal of Psychedelic Studies</i> , 2022, 6, 10-22.	0.5	1
211	Mystical experiences without mysticism: An argument for mystical fictionalism in psychedelics. <i>Journal of Psychedelic Studies</i> , 2022, 6, 48-53.	0.5	2
213	Psychedelic-Assisted Psychotherapy – A Systematic Review of Associated Psychological Interventions. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	17
215	Psychedelics in the treatment of unipolar and bipolar depression. <i>International Journal of Bipolar Disorders</i> , 2022, 10, .	0.8	8
216	Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 1255-1262.	0.6	1
217	Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. <i>CNS Spectrums</i> , 2023, 28, 416-426.	0.7	6
219	Magic Mushrooms – an exploratory look at how mental health professionals feel and think about Psilocybin. <i>Psychiatry Research</i> , 2022, 316, 114727.	1.7	6
220	The promises and pitfalls of facilitated spiritual experiences for the study of religion. <i>Religion, Brain and Behavior</i> , 0, , 1-7.	0.4	0

#	ARTICLE	IF	CITATIONS
221	Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. <i>Clinical Psychologist</i> , 0, , 1-16.	0.5	4
222	Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 140, 104793.	2.9	54
223	Understanding the effects of serotonin in the brain through its role in the gastrointestinal tract. <i>Brain</i> , 2022, 145, 2967-2981.	3.7	21
224	The illusion of knowledge in the emerging field of psychedelic research. <i>New Ideas in Psychology</i> , 2022, 67, 100967.	1.2	5
225	Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT _{2A} Receptor Agonists in Mice. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2436-2448.	1.7	17
226	Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment. <i>Neuroscience Bulletin</i> , 2023, 39, 170-172.	1.5	6
227	Naturalistic Psychedelic Use: A World Apart from Clinical Care. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 379-388.	1.0	12
228	Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. <i>Journal of Psychopharmacology</i> , 2022, 36, 1100-1117.	2.0	54
229	Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes. <i>Molecular Psychiatry</i> , 2023, 28, 59-67.	4.1	6
230	Valproate Adjuvant Cognitive Behavioral Therapy in Panic Disorder Patients With Comorbid Bipolar Disorder: Case Series and Review of the Literature. <i>Psychiatry Investigation</i> , 2022, 19, 614-625.	0.7	3
231	Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The "Velada" Anthropology of Consciousness, 2022, 33, 385-411.	0.5	1
232	Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. <i>Current Psychiatry Reports</i> , 2022, 24, 573-581.	2.1	9
233	Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review. <i>Psych</i> , 2022, 4, 494-515.	0.7	0
234	Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. <i>Journal of Psychopharmacology</i> , 2022, 36, 932-942.	2.0	34
235	Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. <i>Neuropharmacology</i> , 2022, 219, 109214.	2.0	11
236	The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 402-410.	1.0	4
237	Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine. <i>Anthropology of Consciousness</i> , 2022, 33, 358-384.	0.5	0
238	Functional neuroimaging in psychiatry and the case for failing better. <i>Neuron</i> , 2022, 110, 2524-2544.	3.8	36

#	ARTICLE	IF	CITATIONS
239	Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways. <i>Journal of Fungi</i> (Basel, Switzerland), 2022, 8, 870.	1.5	0
240	Skepticism about Recent Evidence That Psilocybin “Liberates” Depressed Minds. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2540-2543.	1.7	9
241	Neurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals. <i>Current Drug Therapy</i> , 2022, 17, .	0.2	0
242	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 5-21.	0.9	21
243	Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. <i>JAMA Psychiatry</i> , 2022, 79, 953.	6.0	217
244	Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica. <i>Anthropology of Consciousness</i> , 0, , .	0.5	1
245	Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP. <i>Addiction</i> , 2022, 117, 3099-3109.	1.7	31
246	Differences across sexes on head-twitch behavior and 5-HT _{2A} receptor signaling in C57BL/6J mice. <i>Neuroscience Letters</i> , 2022, 788, 136836.	1.0	11
247	Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. <i>International Journal of Drug Policy</i> , 2022, 108, 103816.	1.6	4
248	Towards an understanding of psychedelic-induced neuroplasticity. <i>Neuropsychopharmacology</i> , 2023, 48, 104-112.	2.8	65
249	Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 11353.	1.2	7
250	Serotonin 5-HT _{2A} , 5-HT _{2c} and 5-HT _{1A} receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twitch response. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113612.	2.5	22
251	Plasticity of synapses and reward circuit function in the genesis and treatment of depression. <i>Neuropsychopharmacology</i> , 2023, 48, 90-103.	2.8	8
253	The Emerging Field of Psychedelic Psychotherapy. <i>Current Psychiatry Reports</i> , 2022, 24, 583-590.	2.1	4
254	The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. <i>American Journal of Geriatric Psychiatry</i> , 2023, 31, 44-53.	0.6	10
255	The use of classic psychedelics among adults: a Danish online survey study. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 367-378.	0.7	5
256	The psychedelic escape from depression. <i>Nature</i> , 2022, 609, S87-S89.	13.7	5
257	Predictors of attitudes toward psychedelics among psychologists in the USA. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 543-549.	0.8	0

#	ARTICLE	IF	CITATIONS
258	Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. Journal of Psychoactive Drugs, 2023, 55, 501-517.	1.0	7
259	Psychedelics for Alzheimer's Disease Palliative Care. Advances in Psychiatry and Behavioral Health, 2022, 2, 37-46.	0.4	0
260	Microdosing psilocybin for chronic pain: a case series. Pain, 2023, 164, 698-702.	2.0	8
261	Psychedelics for Psychiatric Disorders: Promise, Not Panacea. Psychiatric Annals, 2022, 52, 354-358.	0.1	2
262	The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of Internal Medicine, 2022, 175, 1440-1451.	2.0	11
263	Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine "Implications for dose considerations. Clinical and Translational Science, 2022, 15, 2928-2937.	1.5	11
264	Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biological Psychiatry, 2023, 93, 215-223.	0.7	79
265	Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacological Reviews, 2022, 74, 984-1029.	7.1	10
266	Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 2023, 322, 194-204.	2.0	20
267	Preparing for the Bursting of the Psychedelic Hype Bubble. JAMA Psychiatry, 2022, 79, 943.	6.0	38
268	A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants. Journal of Clinical Psychopharmacology, 2022, 42, 581-588.	0.7	7
269	The treatment of depression " searching for new ideas. Frontiers in Pharmacology, 0, 13, .	1.6	15
270	Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Frontiers in Psychology, 0, 13, .	1.1	11
271	A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology, 2022, 64, 44-60.	0.3	13
272	Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. British Journal of Pharmacology, 2023, 180, 721-739.	2.7	7
273	Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	7
274	Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Transcultural Psychiatry, 2022, 59, 718-724.	0.9	3
275	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and) Tj ETQq1 1 0.784314 rgBT /Overlo	2.0	7

#	ARTICLE	IF	CITATIONS
276	Personalized rTMS for Depression: A Review. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, , .	1.1	2
279	Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapyâ€”A systematized review. Journal of Psychopharmacology, 2022, 36, 1191-1207.	2.0	7
280	Study protocol for â€œMDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle studyâ€• Frontiers in Psychiatry, 0, 13, .	1.3	1
281	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports, 2022, 12, .	1.6	16
282	The neural basis of psychedelic action. Nature Neuroscience, 2022, 25, 1407-1419.	7.1	85
283	Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 2022, 387, 1637-1648.	13.9	304
285	Belief changes associated with psychedelic use. Journal of Psychopharmacology, 2023, 37, 80-92.	2.0	10
286	Psilocybin in Treatment-Resistant Depression. New England Journal of Medicine, 2022, 387, 1708-1709.	13.9	10
289	Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects. Pharmacology Biochemistry and Behavior, 2022, 221, 173474.	1.3	5
290	Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules, 2022, 12, 1618.	1.8	4
291	Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects. NeuroImage, 2022, 264, 119716.	2.1	12
293	Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. International Journal of Neuropsychopharmacology, 2023, 26, 97-106.	1.0	27
294	Psychedelic-Assisted Therapy for People with Eating Disorders. Current Psychiatry Reports, 2022, 24, 767-775.	2.1	5
296	Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. Frontiers in Psychology, 0, 13, .	1.1	6
297	Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. Brain, Behavior, & Immunity - Health, 2022, 26, 100554.	1.3	8
298	Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care. Cambridge Quarterly of Healthcare Ethics, 2022, 31, 464-471.	0.5	10
299	Psychedelics as Standard of Care? Many Questions Remain. Cambridge Quarterly of Healthcare Ethics, 2022, 31, 477-481.	0.5	2
300	Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Pharmacology Biochemistry and Behavior, 2023, 222, 173500.	1.3	20

#	ARTICLE	IF	CITATIONS
301	Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment. <i>Journal of Affective Disorders</i> , 2023, 323, 748-754.	2.0	4
302	Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. <i>Comprehensive Psychoneuroendocrinology</i> , 2023, 13, 100163.	0.7	2
303	Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100410.	1.5	32
304	Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. <i>International Journal of Clinical and Health Psychology</i> , 2023, 23, 100349.	2.7	6
305	ÐÐ•ÐÐ•Ð; ÐÐÐ; ÐŸÐ; Ð•ÐžÐ”Ð•Ð†Ð\$ÐžÐ† Ð¢Ð•ÐÐŸÐ†Ð† Ð¢Ð•Ð†Ð† Ð–ÐÐ\$Ð•ÐÐÐ”Ð•Ð† ÐžÐ\$ÐÐ†ÐÐ. Likarska Sprava,		0
306	Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenonâ€™s predictors and its emotional valence. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
307	Natural Hallucinogens in Mental Health. , 2022, 1, 87-88.		0
308	Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. <i>Journal of Psychopharmacology</i> , 2023, 37, 70-79.	2.0	7
309	Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	3
310	Therapeutic use of psilocybin: Practical considerations for dosing and administration. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
311	Psychedelics and fNIRS neuroimaging: exploring new opportunities. <i>Neurophotonics</i> , 2022, 10, .	1.7	5
312	Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum. <i>Journal of Psychedelic Studies</i> , 2023, 6, 171-175.	0.5	1
313	A unified model of ketamineâ€™s dissociative and psychedelic properties. <i>Journal of Psychopharmacology</i> , 2023, 37, 14-32.	2.0	8
314	Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury. <i>Military Medicine</i> , 2023, 188, e3356-e3362.	0.4	2
315	Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. <i>Heliyon</i> , 2022, 8, e12135.	1.4	3
316	â€œA sense of the bigger picture:â€ A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. <i>PLoS ONE</i> , 2022, 17, e0279073.	1.1	4
317	The economics of psychedelic-assisted therapies: A research agenda. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
318	Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. <i>Journal of Affective Disorders</i> , 2023, 324, 239-249.	2.0	7

#	ARTICLE	IF	CITATIONS
319	Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. Journal of Psychopharmacology, 2023, 37, 3-13.	2.0	3
320	A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. American Journal of Psychiatry, 2022, 179, 892-896.	4.0	14
321	Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome. Psychopharmacology, 2023, 240, 137-147.	1.5	9
322	Novel and emerging treatments for major depression. Lancet, The, 2023, 401, 141-153.	6.3	101
323	Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of “magic mushroom” consumption. Journal of Psychopharmacology, 2023, 37, 49-60.	2.0	24
324	Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. Psychopharmacology, 2023, 240, 115-126.	1.5	0
325	Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. Clinical Pharmacology and Therapeutics, 2023, 113, 822-831.	2.3	33
326	Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery, 2023, 92, 680-694.	0.6	2
327	A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends in Cognitive Sciences, 2023, 27, 139-159.	4.0	18
328	Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. Psychopharmacology, 2023, 240, 27-40.	1.5	5
329	Altered States of Consciousness During Ceremonial San Pedro Use. International Journal for the Psychology of Religion, The, 2023, 33, 309-331.	1.3	0
330	Entheogenic Spirituality: Characteristics of Spiritually Motivated Psychedelics Use. International Journal for the Psychology of Religion, The, 0, , 1-17.	1.3	1
331	Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans. Biological Psychiatry, 2023, 93, 1061-1070.	0.7	23
333	On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med, 2023, 4, 8-9.	2.2	4
334	Ongoing phase 2/3 trials of psychotropic drugs: is help finally on the way?. World Psychiatry, 2023, 22, 80-82.	4.8	0
335	The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry, 2023, 22, 48-74.	4.8	40
336	5-HT _{2A} Rs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. ACS Chemical Neuroscience, 2023, 14, 351-358.	1.7	22
337	Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chemical Neuroscience, 2023, 14, 468-480.	1.7	33

#	ARTICLE	IF	CITATIONS
339	Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. <i>EClinicalMedicine</i> , 2023, 56, 101809.	3.2	73
340	Psilocybin for Depression: From Credibility to Feasibility, What's Missing?. <i>Pharmaceuticals</i> , 2023, 16, 68.	1.7	5
342	Direct Quantitation of Psilocybin and Psilocin by One-Dimensional ¹ H and ³¹ P qNMR in a revived Greek specimen of <i>Psilocybe cyanescens</i> . <i>Planta Medica</i> , 2022, , .	0.7	0
343	Phytochemicals That Act on Synaptic Plasticity as Potential Prophylaxis against Stress-Induced Depressive Disorder. <i>Biomolecules and Therapeutics</i> , 2023, 31, 148-160.	1.1	6
344	The costs and benefits of psychedelics on cognition and mood. <i>Neuron</i> , 2023, 111, 614-630.	3.8	7
345	Educational Materials and Image Induction Increase Treatment Credibility. <i>Journal of Psychoactive Drugs</i> , 2024, 56, 56-65.	1.0	0
346	New antidepressants: monoamines and beyond. <i>The Prescriber</i> , 2023, 34, 17-20.	0.1	1
347	Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder. <i>Biological Psychiatry Global Open Science</i> , 2023, 3, 663-672.	1.0	2
348	The psychedelic renaissance: can psilocybin possibly combat depression?. <i>International Journal of Surgery Global Health</i> , 2022, 5, e89-e89.	0.2	0
349	Possible psychedelic therapeutic mechanism. <i>Science</i> , 2023, 379, 642-643.	6.0	0
350	Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. <i>Frontiers in Psychology</i> , 0, 14, .	1.1	3
351	Mystical and Ego-Dissolution Experiences in Ayahuasca and Jurema Holistic Rituals: An Exploratory Study. <i>International Journal for the Psychology of Religion, The</i> , 2023, 33, 332-360.	1.3	3
352	Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	4
353	Unblinding and demand characteristics in the treatment of depression. <i>Journal of Affective Disorders</i> , 2023, 328, 1-5.	2.0	2
354	Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. <i>Neuropharmacology</i> , 2023, 231, 109504.	2.0	7
355	Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. <i>Journal of Affective Disorders</i> , 2023, 326, 105-110.	2.0	20
356	Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. <i>Military Psychology</i> , 2024, 36, 184-191.	0.7	2
357	Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. <i>Psychopharmacology</i> , 2023, 240, 827-836.	1.5	8

#	ARTICLE	IF	CITATIONS
358	Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. <i>Journal of Affective Disorders</i> , 2023, 327, 120-127.	2.0	32
359	Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	8
360	N,Nâ€dimethyltryptamine affects electroencephalography response in a concentrationâ€dependent mannerâ€”A pharmacokinetic/pharmacodynamic analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 474-486.	1.3	5
361	Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
362	Experiences of psilocybin treatment for clinical conditions: A qualitative metaâ€synthesis. <i>International Journal of Mental Health Nursing</i> , 2023, 32, 1025-1037.	2.1	4
363	Major depressive disorder and the gut microbiome: what is the link?. <i>Annals of General Psychiatry</i> , 2023, 36, e100973.	1.1	5
365	Acute psilocybin enhances cognitive flexibility in rats. <i>Neuropsychopharmacology</i> , 2023, 48, 1011-1020.	2.8	11
366	Alkaloids from Fungi. , 2023, , 529-554.		0
367	Pursuit of the Miraculous or Just Piling up Confusion. , 2022, , 135-211.		0
369	Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 601-611.	1.0	0
370	Neue und experimentelle medikamentÃŕse Therapieverfahren. , 2022, , 203-218.		0
371	Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. <i>American Journal of Psychiatry</i> , 2023, 180, 190-199.	4.0	16
372	The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. <i>International Medical Case Reports Journal</i> , 0, Volume 16, 109-115.	0.3	1
373	Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. <i>Journal of Psychopharmacology</i> , 2023, 37, 733-748.	2.0	8
374	Next generation antidepressants with novel mechanisms for treatment resistant depression. <i>Progress in Brain Research</i> , 2023, , .	0.9	1
375	Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics. <i>Consciousness and Cognition</i> , 2023, 110, 103494.	0.8	7
376	Rethinking the medication management of major depression. <i>Expert Review of Neurotherapeutics</i> , 2023, 23, 331-363.	1.4	1
377	Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. , 0, , .		0

#	ARTICLE	IF	CITATIONS
378	Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0
379	Psychedelics: preclinical insights provide directions for future research. <i>Neuropsychopharmacology</i> , 2024, 49, 119-127.	2.8	7
380	Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. <i>Journal of Psychopharmacology</i> , 2023, 37, 698-706.	2.0	43
382	Role of Psychedelics in Treatment-Resistant Depression. <i>Psychiatric Clinics of North America</i> , 2023, 46, 291-305.	0.7	3
383	Importance of achieving rapid treatment response in major depressive disorder. <i>CNS Spectrums</i> , 2023, 28, 521-525.	0.7	1
384	Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. <i>Journal of Psychiatric Research</i> , 2023, 161, 364-370.	1.5	24
385	Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. <i>Psychiatric Services</i> , 2023, 74, 838-846.	1.1	17
386	The need for establishing best practices and gold standards in psychedelic medicine. <i>Journal of Affective Disorders</i> , 2023, 332, 47-54.	2.0	7
387	Psychotherapy with Psilocybin for Depression: Systematic Review. <i>Behavioral Sciences (Basel)</i> , 2023, 12, 1042.	1.0	4
388	Clinical pharmacological innovation in the treatment of depression. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 349-362.	1.3	7
389	Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults. <i>Journal of Personality Disorders</i> , 2023, 37, 131-155.	0.8	3
390	Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. <i>Neuropharmacology</i> , 2023, 233, 109528.	2.0	7
391	5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. <i>Neuropsychopharmacology</i> , 2023, 48, 1257-1266.	2.8	11
392	Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	5
393	Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. <i>Cureus</i> , 2023, , .	0.2	3
394	G protein coupled receptors as targets for transformative neuropsychiatric therapeutics. <i>American Journal of Physiology - Cell Physiology</i> , 0, , .	2.1	1
414	Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
416	How medical cannabis may influence the future of Western medicine. , 2023, , 3-14.		0

#	ARTICLE	IF	CITATIONS
417	Timing is key for behavioural benefits of psychedelics. Nature, 2023, 618, 677-678.	13.7	1
422	Bioprospecting. , 2024, , 341-356.		0
425	Visualizing drug actions on dendrites: psilocybin and other classic psychedelics. , 2023, , .		0
441	Does acute stress play a role in the lasting therapeutic effects of psychedelic drugs?. Neuropsychopharmacology, 0, , .	2.8	0
448	Neurobiological Foundations of Psychotherapies. , 2023, , 1-21.		0
451	The Health and Clinical Benefits of Medicinal Fungi. Advances in Biochemical Engineering/Biotechnology, 2023, , .	0.6	0
455	Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology, 2024, 49, 104-118.	2.8	4
458	The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer's Disease. Current Geriatrics Reports, 2023, 12, 149-155.	1.1	1
481	Neuroimaging in psychedelic drug development: past, present, and future. Molecular Psychiatry, 2023, 28, 3573-3580.	4.1	2
482	Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology, 0, , .	2.8	4
483	Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Molecular Psychiatry, 2023, 28, 3595-3612.	4.1	4
484	The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology, 2024, 49, 227-245.	2.8	6
494	Preclinical models of treatment-resistant depression: challenges and perspectives. Pharmacological Reports, 2023, 75, 1326-1340.	1.5	0
517	Medical Use of Cannabinoids and Psychedelic Compounds. , 2023, , 1-30.		0
528	Psychoactive drugs. , 2024, , 397-407.		0
532	Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacological Reports, 0, , .	1.5	1
534	Technical and clinical considerations for electroencephalography-based biomarkers for major depressive disorder. , 2023, 2, .		0
536	Antidepressiva. , 2023, , 1-213.		0

#	ARTICLE	IF	CITATIONS
540	The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological Reports, 2023, 75, 1313-1325.	1.5	2
542	Psilocybin and Other Classic Psychedelics in Depression. Current Topics in Behavioral Neurosciences, 2023, , .	0.8	0
543	Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. Pharmacological Reports, 2023, 75, 1341-1349.	1.5	0
571	Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances. , 2023, , 1-34.		0
585	Traitements psychiatriques et soins en addictologie. , 2023, , 593-599.		0
589	Psychedelic Psychiatry. , 2024, , .		0
614	Depressive and anxiety disorders. , 2024, , .		0
624	Bringing It Home and Carrying It Forward. , 2024, , 252-262.		0
627	Integration Sessions. , 2024, , 204-251.		0
628	INTRODUCTION: A New Approach for the Whole Person. , 2024, , 1-9.		0
629	An Overview of Psychedelic-Assisted Therapy. , 2024, , 10-30.		0
632	Medicine Sessions. , 2024, , 167-203.		0
634	Preparation Sessions. , 2024, , 132-166.		0
635	Considerations Prior to Meeting With a Participant. , 2024, , 93-131.		0
636	EMBARC Mechanisms of Change in the Treatment of Depression. , 2024, , 70-92.		0
637	Introduction to the EMBARK Approach. , 2024, , 31-69.		0
642	Medical Use of Cannabinoids and Psychedelic Compounds. , 2024, , 1-29.		0